Dendritic cell therapy is a form of cancer immunotherapy that utilizes the body's own immune system to fight cancer cells. It is considered a promising approach for patients with various cancers, including colon cancer. Regarding the latter, this disease is one of the most prevalent malignancies worldwide [1]. According to the American Cancer Society, over 158,850 new cases of colorectal cancer will be diagnosed in the US in 2026. After decades of decline, overall rectal cancer incidence has increased by 1% per year since 2018 and now accounts for about one in three (32%) CRC diagnoses [2]. To manage the symptoms of this disease, surgery, chemotherapy, and radiation remain important. However, these methods come with limitations. This is why the research community has turned its attention to immunotherapy with dendritic cell vaccination (DCV), as this approach can improve outcomes, even for those with metastatic colon cancer.
Before discussing how DCV works, we note that the importance of dendritic cells in adaptive immunity was recognized in 2011, when the Nobel Prize in Physiology or Medicine was awarded to Ralph Steinman for his discovery of these immune cells [3]. Dendritic cells (DCs) are essential: they help identify abnormal structures, such as tumor cells, and "teach" the immune system to destroy them.
One of the questions many might ask is: where is this treatment available? Currently, Germany is one of the few countries in the world where certified immunotherapy centers offer personalized dendritic cell vaccines customized to each patient's tumor genetics. German oncological centers report remission rates exceeding 90% in early-stage colon cancer and around 80% in advanced cases in patients where DCV was integrated into a personalized treatment plan. Receiving dendritic cell therapy for colon cancer in Germany offers a unique opportunity for patients abroad to access innovative care.
Dendritic Cells and the Basis of Dendritic Cell Therapy in Colon Cancer
Dendritic cell therapy is a type of cancer treatment within the broader category of cancer immunotherapy. Chemotherapy attacks all rapidly dividing cells. In contrast, DCs immunotherapy can train the body's immune system to specifically recognize and eliminate tumor cells while sparing healthy tissue. Simply said, this approach, as mentioned above, can target cancer. This can result in fewer side effects and, in many cases, significantly improve long-term outcomes.
What Are Dendritic Cells?
Dendritic cells are specialized immune cells that help activate the body's adaptive immune system. They are often referred to as the "officers" of the immune response. The reason is that they are among the first to detect abnormal or foreign substances (e.g., cancer cells) and present these threats to T-lymphocytes (T-cells) for destruction. These cells can capture and process tumor antigens, migrate to lymph nodes, present processed antigens to immature T-cells, and activate cytotoxic (CD8+) T-cells that directly fight cancer [4].
This process is known as antigen presentation. Basically, it is the foundation of how DCV are designed to work.
Mechanism of Action in Colon Cancer
Dendritic cell therapy, colon cancer patients receive, works in several steps:
Blood Collection and Immune Cell Isolation. First, approximately 200 ml of the patient's blood is drawn. It is transported under controlled conditions to a certified clean room. Then, the blood undergoes centrifugation to separate its components. As a result of this process, the red blood cells and granulocytes (nonspecific immune cells) are discarded. In turn, the lymphocyte-rich fraction is retained. This fraction contains the precursor cells needed to generate dendritic cells.
Vaccine Preparation and Antigen Loading. In this step, the immune cells are cleaned and cultured in a nutrient-rich medium. Specific growth factors are added to promote the maturation of DCS precursors. From the beginning of this process, autologous tumor antigens are introduced. These antigens serve to "educate" dendritic cells. Colorectal cancer tumor-specific markers, such as carcinoembryonic antigen (CEA), mucin 1 (MUC1), Wilms' tumor gene 1 (WT1), and mutated p53 protein, can be used for this process [5].
Dendritic Cell Maturation and Quality Control. Over the course of 7 days, the dendritic cells mature in the incubator. When viewed under a microscope, one can observe that these cells develop distinctive hair-like extensions, which characterize them as mature antigen-presenting cells. The vaccine undergoes strict quality checks before it can be used. The aim is to assess surface markers, cell count, and viability using flow cytometry.
Immune Activation and Vaccination. Lastly, the mature dendritic cells are harvested and cleaned. After that, they are placed into sterile syringes. Then, they are administered via subcutaneous injection, typically in the groin region. Following immunization, the patient receives a high-dose vitamin infusion and is discharged the same day. These dendritic cells travel to the lymph nodes, where they present tumor antigens to T-cells, activating cytotoxic (CD8+) T-cells and memory T-cells for long-term immune surveillance.
According to research, dendritic cell-based vaccines significantly increase CD8+ T-cell activity in patients with colorectal cancer, a finding that correlates with slower tumor progression and improved survival.
The Clinical Value of Dendritic Cell Therapy in Colon Cancer Treatment
DC therapy is clinically significant because it restores immune surveillance, enabling the immune system to recognize and eliminate tumor cells that have evaded detection. It can be highly effective at any stage of colon cancer. It is primarily used in multimodal cancer management, alongside surgery, chemotherapy, radiotherapy, and immune checkpoint inhibitors to boost overall effectiveness, eradicate residual disease, and enhance clinical outcomes.
Impact on the Colon Cancer Microenvironment
Research shows that tumors frequently develop an immunosuppressive microenvironment, enabling them to evade immune detection [6]. This environment hampers native dendritic cells, recruits regulatory T-cells that inhibit immune responses, and stimulates blood vessel formation (angiogenesis) to supply nutrients to tumor cells.
However, DCV helps disrupt this environment by reintroducing healthy, immunocompetent dendritic cells, enhancing immune surveillance, and supporting anti-angiogenic effects.
In fact, some studies suggest that DCV may help destroy tumor blood vessels, starving the cancer of oxygen and nutrients. Moreover, when combined with chemotherapy, dendritic cells benefit from the "danger signals" released by dying tumor cells. This makes it easier for the immune system to recognize residual cancer.
The success of dendritic cell therapy for colon cancer has been demonstrated in several studies in Germany and around the world.
Remission, Disease-Free, and Overall Survival in Colon Cancer
A meta-analysis of seven studies (533 colorectal cancer patients) showed that the combination of dendritic cell-cytokine-induced killer (DC-CIK) immunotherapy with chemotherapy significantly improved:
- 2-year overall survival: 76% vs. 69% with chemotherapy alone (P = 0.009)
- 3-year overall survival: 80% vs. 61% (P = 0.002)
- 1-year disease-free survival: 86% vs. 63% (P < 0.0001)
This means that DCV can positively affect both recurrence prevention and long-term survival [7].
Progression-Free Survival and Immune Activation in Colon Cancer
In this regard, studies of DC-CIK therapy have reported significant increases in CD4+ T-cell counts, reflecting enhanced immune activation [8]. In smaller studies involving DCV targeting WT1 antigens, immunity persisted for two years. This correlates with prolonged disease-free survival and overall survival [9].
Recurrence Prevention and Quality of Life in Colon Cancer
As previously noted, one of the most valuable aspects of dendritic cell therapy is its potential to prevent recurrence. By inducing long-term immune memory, dendritic cells continue to recognize and destroy cancer cells even after apparent remission. In addition to clinical outcomes, DCV contributes to a higher quality of life due to its favorable safety profile. A five-year study shows that nearly 71% of patients who received DCV were cancer-free at nearly 5 years [10].
Immune Cells Matter
The success of dendritic cell immunotherapy depends on the effective activation of immune cells:
- CD4+ and CD8+ T-lymphocytes are boosted significantly, enhancing tumor surveillance and control.
- Elevated dendritic cell infiltration within tumors correlates with improved progression-free and overall survival.
This evidence confirms the critical role of immune cells and DCV in achieving positive outcomes for patients with colon cancer, especially when combined with chemotherapy.
The Use of Dendritic Cell Therapy in Colon Cancer at Different Stages
Dendritic cell therapy for bowel cancer is a therapeutic option for various categories of patients. It is considered beneficial when standard treatments are insufficient, unavailable, or ineffective. Eligibility for the colon cancer vaccine is determined by clinical stage, tumor characteristics, and individual treatment goals.
Ideal candidates for DCV are:
Patients After Cytoreductive Surgery. In general, the most favorable time to initiate dendritic cell vaccination is after cytoreductive surgery. This is typically done in patients with localized disease or isolated liver metastases, when it is feasible to achieve complete or near-complete tumor resection.
The main goal is to remove the tumor mass surgically. Then, the dendritic cell vaccine allows targeting of residual micrometastases. In this regard, research found that patients who underwent DCV following tumor debulking had significantly improved recurrence-free survival compared to those who received surgery alone.
Patients with Metastatic Colon Cancer and Liver Involvement. As the available evidence demonstrates, up to 20% of colon cancer patients present with unresectable liver metastases at diagnosis. In these cases, surgery may not be possible. Yet, DCV remains an option.
Even without tumor resection, the immune system can be trained to recognize and attack tumor-associated antigens expressed by metastatic cells. The surface of colon cancer tissues contains highly immunogenic molecules such as CEA, WT1, MUC1, and mutated p53 protein. As mentioned above, these markers are not found in healthy tissue, making them ideal targets for personalized vaccination protocols.
Patients Not Eligible for Surgery or Chemotherapy. Some patients may be ineligible for standard treatments due to age, comorbidities, or poor general condition. However, dendritic cell colon cancer therapy can be used to treat these individuals. For them, it can offer a non-toxic and immunologically active alternative.
As previously noted, DCV avoids the harsh side effects of chemotherapy. As such, it may improve quality of life and slow tumor progression without the need for hospitalization. In addition, dendritic cell therapy for colon cancer can also preserve immune function. Therefore, it allows for future combination therapies if the patient's condition improves.
Patients with Recurrent Disease. In modern colon cancer treatment, recurrence prevention is a central goal, especially after apparent remission. The good news is that DCV can be effective in managing relapsed colorectal cancer, particularly when other therapies have failed.
As discussed in the literature, recurrent disease often develops due to immune evasion by cancer cells. However, dendritic cell therapy helps reprogram the immune system to detect and eliminate recurring malignant cells. Therefore, patients who relapse after radiation therapy, chemotherapy, or targeted treatments may benefit from vaccination to extend survival and maintain symptom control.
Genetic Profiling and Biomarkers
Modern oncology uses biomarker analysis to identify suitable candidates for immunotherapy. In DCV, tumor tissue or circulating tumor cells are analyzed to detect neoantigens. These are new mutations that arise in cancer and are recognizable by the immune system.
Specifically, a liquid biopsy or a tumor biopsy provides DNA or RNA used in vaccine manufacturing. The presence of mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status may enhance the effectiveness of dendritic cell-based immunotherapy by increasing the antigenic load.
Expert Insights from Prof. Gansauge on Dendritic Cell Therapy in Cancer Treatment
The effectiveness of the dendritic cell bowel cancer vaccine is supported not only by clinical data. In this article, we want to introduce our readers to Professor Frank Gansauge. He is a German surgeon and immunologist with over 22 years of experience in developing and applying dendritic cell vaccines. Professor Gansauge is the founder of LDG Laboratories in Germany. He has personally overseen more than 2,500 dendritic cell therapy protocols. His innovative approach has become one of the most trusted methods for personalized cancer treatment abroad.
To fully understand how Germany integrates immunotherapy into comprehensive oncology programs, we recommend watching Professor Gansauge's interview:
Growing Patient Trust in Dendritic Cell Therapy for Colon Cancer Treatment
The trust in dendritic cell treatment for bowel cancer is rising among patients from all around the world. The increased interest is driven by high-quality, modern technologies used in vaccine development, as well as high personalization. Dendritic cell vaccination of patients with metastatic colorectal cancer is viewed as a promising option because of its lower treatment burden and reduced toxicity compared to conventional therapies, which are often associated with significant side effects and diminished quality of life. In countries like Germany, where innovative therapies are integrated into treatment plans, there is a growing demand from international patients for cancer care.
Possible Side Effects and Contraindications of Dendritic Cell Therapy for Colon Cancer
Dendritic cell vaccination is generally considered safe because the vaccine is made from the patient's own immune system. This reduces the body's response because it treats the vaccine as its own and does not modulate the reaction to it. As with any vaccination, it can have some side effects that include:
- Low fever
- Fatigue
- Swelling at the injection site
- Headache
- Short-term chills
Some of the limitations of DCV use are:
- Severe immunodeficiency with low immune cell count
- Organ failure during end-stage disease
- Hematologic malignancies, where the tumor directly suppresses dendritic cell function
- Severe autoimmune conditions
Comparison of Traditional vs. Dendritic Cell-Based Therapy
| Treatment option | Indications | Side effects | Disadvantages | Benefits |
|---|---|---|---|---|
| Dendritic cell therapy | all malignant tumors of all stages | minimal (flu-like symptoms) | individualized manufacturing is available at specialized centers only | highly personalized, life-long immunity after a single injection, minimal side effects |
| Standard immunotherapy: without individual production | specific malignant tumors of all stages | mild to moderate (rash, fatigue) | risk of severe immune-related adverse events, high proportion of non-responders, need for continuous long-term treatment | no need for patient-specific cell production, broader availability across treatment centers |
| Chemotherapy | malignant tumors of all stages | severe (nausea, hair loss) | systemic side effects, low quality of life during treatment, development of resistance over time, and high recurrence rate | widely available, effective for systemic disease, and temporarily slows tumor growth |
Step-by-Step Process of Dendritic Cell Therapy for Colon Cancer
Germany is internationally recognized for its advancements in cancer immunotherapy, particularly in the development and administration of DCV. The dendritic cell treatment follows a standardized yet highly personalized two-step protocol, conducted in certified immunotherapy centers that meet the highest safety and quality standards.
This therapeutic process is carried out in a comfortable outpatient setting, making it accessible and minimally disruptive to a patient's daily life. The entire procedure typically spans a few weeks, with vaccine development occurring under advanced laboratory conditions, but the timing can vary depending on the chosen clinic.
Day 1: First appointment
During the first appointment, the patient learns about the procedure. Their medical history is obtained, and possible therapeutic options, nutrition, and complementary medicines are discussed with the patient. At the end, the patient gives their informed consent to receive the DCV.
Day 2: Blood Collection and Vaccine Development
Blood Collection. The patient has a blood draw of around 150-200 ml, like a typical blood donation. Patients may have breakfast before blood collection. It is then followed by an infusion of vitamin C and vitamin B-complex, as well as an intramuscular vitamin D injection (50,000 IU) to stimulate immune cells (NK).
The blood is transported under stable conditions to a certified cleanroom laboratory, where it is centrifuged to separate its components.
As explained in the mechanism of action, the red blood cells and granulocytes (non-specific immune cells) are discarded, while the lymphocyte-rich fraction– containing precursor cells that develop into dendritic cells– is retained. They are then cultivated in a nutrient-rich medium with interleukins and growth factors. Over the course of 3-5 days, monocytes mature into dendritic cells capable of presenting tumor antigens to T-cells.
Antigen Loading and Maturation. In the laboratory, the maturing dendritic cells are exposed to tumor-specific antigens– whether derived from the patient's plasma (most often), tumor tissue, or synthetic peptides. The cells are monitored under a microscope during the 7-day maturation process to ensure proper growth and development.
Dendritic cells undergo quality-control testing to assess surface markers, viability, and cell count using flow cytometry. Once approved, the final vaccine–containing millions of mature, trained dendritic cells–is prepared for administration.
Day 9: Vaccine Administration and Cryopreservation
This step involves the actual delivery of the dendritic cell bowel cancer treatment injections and logistical planning for subsequent treatments.
Subcutaneous Vaccination. The vaccine is administered via a subcutaneous injection, typically in the inguinal region (groin) or near the umbilicus (navel) once any surgical wounds have healed. An infusion containing vitamin C and vitamin B-complex is given, as well as an intramuscular vitamin D injection (50,000 IU). The procedure is brief and painless, usually completed within an hour, and patients can return home the same day.
Cryopreservation of Vaccines. To avoid repeated leukapheresis or blood collection, excess vaccine doses are cryopreserved for future colon cancer treatment injections. These preserved DCs maintain full functionality due to strict EU-GMP laboratory protocols. Patients may receive 3 to 6 injections over several months, depending on the clinical response and disease progression, although in some cases, a single vaccination may be sufficient.
Logistics and Support of Colon Cancer Patients
- DC therapy for bowel cancer in Germany is usually completed within 4-6 weeks from initial consultation
- Continuous communication with the clinic ensures careful monitoring and adaptable scheduling
- Patients traveling to Germany for cancer treatment can schedule short, comfortable visits with minimal disruption
This protocol allows German clinics to deliver advanced care while prioritizing patient convenience, safety, and personalized medicine.
Clinic Selection for Dendritic Cell Therapy for Colon Cancer in Germany
The dendritic cell bowel cancer treatment in Germany that patients can receive is not available in many countries. This is due to the need for certified immunotherapy centers with advanced laboratory equipment, strict regulatory approval, and GMP-compliant cell-processing facilities, all of which require top specialists and scientists to create personalized cancer vaccines from the patient’s own immune cells. The treatment is performed in selected centers in Switzerland, Japan, and the United States, but it is most developed in Germany.
Dendritic cell therapy, bowel cancer in Germany treatment, is available in several hospitals throughout the country, making them the most experienced in the world. Hospitals in Germany are known for their safe, effective, and personalized production of DCs vaccine. These centers stand out thanks to the integration of DCV in personalized treatment plans.
Look at some healthcare centers that offer cutting-edge diagnostic tools and therapies like DCV:
- Laboratories Dr. Gansauge in Berg. This clinic has worldwide recognition for its exceptional experience and success rates in DC therapy. They integrate advanced research into comprehensive treatment plans with emphasis on the patient’s comfort and quality of life.
- IOZK Immuno-Oncology Center in Cologne. This is a reputable immunology center that combines DCV with other treatments to deliver optimal results and prolong survival.
- Praxisgemeinschaft für Zelltherapie in Duderstadt. It’s a German modern research facility dedicated to molecular therapies, including DCV. Their goal is to offer personalized treatment strategies using cutting-edge laboratory technologies.
Patients traveling abroad for personalized cancer immunotherapy choose German hospitals for their innovative approach and comprehensive cancer care when their goal is to receive advanced therapies that combine DCV with surgery, chemotherapy, and other immunotherapies.
Cost of Dendritic Cell Therapy for Colon Cancer in Germany
The price of treatment depends on various factors, such as the country, clinic, and level of personalization involved in producing the dendritic cell vaccine. Colon cancer patients in Germany receive a vaccination developed in GMP laboratories, balancing cost, quality, and accessibility, with prices typically ranging from €20,000 to €38,000. On the other hand, in the USA, the price ranges from €100,000 to €150,000 due to higher healthcare costs. Also, the waiting times can be significantly longer due to restricted access to modern technologies.
Take a look at the comparison of price and availability of DCV in different countries:
Cost of Dendritic Cell Therapy in Different Countries
| Country | Dendritic cell therapy price |
|---|---|
| Germany | €20,000 - €38,000 |
| USA | €100,000 - €150,000 |
| Great Britain | Not available |
| Australia | Not available |
* Costs are approximate and may vary depending on the hospital and individual patient requirements.
Increasing the Effectiveness of Dendritic Cell Therapy in Colon Cancer by Combining It with Other Treatments
We hope our readers now see that DCV is a great strategy to incorporate in colon cancer treatment. However, we must note that its full potential is shown when combined with conventional modalities (e.g., chemotherapy, radiation therapy, and immune checkpoint inhibitors). These multimodal combination therapies are referred to as immuno-chemo protocols. They represent a new standard in personalized cancer treatment, particularly in advanced or recurrent disease.
Dendritic Cell Therapy and Changes in Tumor Microenvironment
Cancer cells can alter the surrounding tissue to form an immunosuppressive tumor microenvironment. Main features of this environment include:
- Dysfunctional immune cells, including dendritic cells and T-cells
- Abundant regulatory T-cells that suppress immune responses
- Overexpression of PD-L1, a protein that inhibits T-cell activity
- Increased secretion of cytokines that promote tumor progression
By combining DCV with chemotherapy or checkpoint inhibitors, doctors can break this protective barrier. They can reactivate the immune system and achieve better tumor control.
Clinical Use in Germany
German oncology clinics use DCs immunotherapy in conjunction with:
Chemotherapy. These regimens induce immunogenic cell death, releasing tumor antigens. Then, the released antigens are "captured" by administered dendritic cells, enhancing T-cell activation. For example, a study showed that patients with stage IV colon cancer who received dendritic cell vaccines combined with chemotherapy drugs had longer overall survival and disease-free survival than those on chemotherapy alone [12].
Immune Checkpoint Inhibitors. These drugs restore the function of exhausted T-cells. When paired with dendritic cell vaccination, they amplify anti-tumor activity. They are considered especially effective in tumors with MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair).
Radiation Therapy. Radiation damages cancer cells and releases tumor antigens. Dendritic cell therapy then "trains" the immune system to recognize and attack those same antigens. This approach can be used in patients with localized rectal cancer before surgery.
Regional Chemotherapy (RC). RC initially helps shrink tumors by delivering a high dose of cancer-fighting drugs straight to the tumor site. When combined with DCV, it offers an extra boost in controlling the tumor locally by also reaching out to target any remaining tumors systemically.
Advantages of Combination Therapy in Colon Cancer
Patients who receive combination therapy benefit from the positive effects of multiple approaches while minimizing toxicity. Some of the advantages include:
- Stronger immune activation against tumor cells
- Lower chemotherapy doses are needed to reduce side effects
- Delayed tumor progression and longer survival
- Improved quality of life, especially in advanced stages
- Better recurrence prevention, even in high-risk cases
It is concluded that a combination of chemo protocols with dendritic cell vaccination, patients, metastatic colorectal cancer survivors, experienced enhanced overall quality of life and tumor control.
A Personalized Colon Cancer Treatment Strategy
In view of the information provided above, we want to add that, when receiving treatment for cancer in Germany, patients should understand that combination therapy is never one-size-fits-all. Oncologists always evaluate each case individually to determine the best mix of treatment approaches.
Dendritic Cell Therapy for Colon Cancer in Germany with Booking Health
It can sometimes be difficult to find the best treatment strategy for your individual clinical case. Most patients are already tired from multiple treatment sessions, have received opinions of many specialists, and have tried different therapeutic approaches. They often feel lost amid all the information from the doctors. In such a situation, it is easy to opt for a first-line treatment or follow standardized therapeutic protocols that carry a long list of adverse effects, rather than selecting highly specialized, innovative treatment options.
To help you make an informed decision and receive a personalized cancer management plan that fits your unique clinical needs, consider consulting medical experts at Booking Health. With over 12 years of experience in providing the latest medical innovations, Booking Health has a strong track record of crafting tailored, comprehensive cancer care programs for everyone. As a trusted company, Booking Health is here to offer you personalized dendritic cell therapy for colon cancer. We make everything easy by providing direct clinic booking and full support throughout your journey– from organizing your appointment to offering help during your treatment. Our goal is to support you every step of the way. We provide:
- Evaluation and examination of medical reports
- Development of the medical care program
- Selection of an appropriate location for treatment
- Preparation of medical documents and delivery to an appropriate clinic
- Preliminary consultations with clinicians to develop medical care programs.
- Guidance from experts during hospital stays
- Follow-up care after the patient returns to their home country following the completion of the medical care program.
- Handling formalities as part of preparing for the medical care program.
- Coordination and management of the patient's stay in a foreign country
- Help with visas and tickets
- A personal coordinator and interpreter available 24/7.
- Clear budgeting with no hidden fees
Health is an essential part of our lives. Entrusting its management to experts with proven experience and a solid reputation is crucial. Booking Health is a reliable partner that helps you achieve better health and an improved quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with a vaccine for colon cancer with leading specialists in this field.
Personalized Dendritic Cell Treatment: Experience with Booking Health
Frequently Asked Questions About Dendritic Cell Therapy for Colon Cancer
Send request for treatmentDendritic cell treatment for bowel cancer is an innovative therapy that trains the immune system to recognize and fight cancer while complementing other treatments. Dendritic cell bowel cancer vaccine creation is performed from the patient's tumor cells and immune cells. That’s why dendritic cell therapy for bowel cancer is getting international recognition and integration into personalized treatment plans.
Dendritic cell therapy costs between 20,000 and 38,000 euros, varying based on additional treatments and individual needs. The price covers the complete treatment program from consultation to vaccine administration.
German clinics offer this Nobel Prize-winning treatment with minimal side effects, combining immunotherapy with traditional approaches. Patients receive care from experienced medical teams in state-certified facilities with proven success rates.
Dendritic cell therapy for colon cancer is a form of immunotherapy that uses a patient's own dendritic cells to train the immune system to recognize and attack colon cancer cells. These specialized immune cells are extracted and exposed to tumor antigens in a lab. Then, they are reintroduced into the body to activate a targeted immune response against the cancer.
Colon cancer patients are eligible for dendritic cell therapy at various stages of treatment. In particular, it may be beneficial for those with metastatic colon cancer, recurrence after conventional therapies, or who are unable to tolerate chemotherapy. It is also used for recurrence prevention after tumor resection, especially in cases with a high risk of relapse.
Clinical studies show that dendritic cell therapy for colon cancer can lead to improved survival, particularly in combination with other therapies. It activates immune cells that target and destroy tumor tissue. This approach also delays tumor progression and reduces recurrence rates.
Several certified immunotherapy centers offer advanced colon cancer treatment with dendritic cells in Germany. These specialized clinics have the infrastructure to develop personalized vaccines and integrate them into comprehensive care programs.
Benefits of DCV for colon cancer include low toxicity and significant recurrence prevention by training the immune system to recognize residual cancer cells. It can also improve quality of life and support long-term immune surveillance via a naturally activated immune system.
Yes, it is often part of combination therapy. Specifically, immuno-chemo protocols integrate DCs with chemotherapy, radiation, or checkpoint inhibitors to enhance immune cell activation and improve treatment outcomes.
The Booking Health service simplifies the organization of treatment for patients seeking cancer treatment abroad. Their experts help select one of the best German oncology clinics for your case and handle all arrangements. By using this company's services, patients gain access to leading German specialists and receive continuous support throughout the treatment process.
Choose treatment abroad and you will for sure get the best results!
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Yana Dmytryshyn. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] Meng Wang, Chaojing Zheng, Zitong Wang et al. Colorectal cancer: highlight the clinical research current progress. Holist Integ Oncol 4, 17 (2025). doi: 10.1007/s44178-025-00152-w. [DOI]
[2] Siegel RL, Wagle NS, Star J, Kratzer TB, Smith RA, Jemal A. Colorectal cancer statistics, 2026. CA Cancer J Clin. 2026 Mar-Apr;76(2):e70067. doi: 10.3322/caac.70067. [DOI] [PubMed]
[3] Volchenkov R, Sprater F, Vogelsang P, Appel S. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
[4] Gardner A, de Mingo Pulido Á, Ruffell B. Dendritic Cells and Their Role in Immunotherapy. Front Immunol. 2020 May 21;11:924. doi: 10.3389/fimmu.2020.00924. [DOI] [PMC free article]
[5] Kajihara M, Takakura K, Kanai T, Ito Z, Saito K, Takami S, Shimodaira S, Okamoto M, Ohkusa T, Koido S. Dendritic cell-based cancer immunotherapy for colorectal cancer. World J Gastroenterol. 2016 May 7;22(17):4275-86. doi: 10.3748/wjg.v22.i17.4275. [DOI] [PMC free article]
[6] Racacho KJ, Shiau YP, Villa R, Mahri S, Tang M, Lin TY, Li Y. The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches. Front Immunol. 2025 Sep 22;16:1621812. doi: 10.3389/fimmu.2025.1621812. [DOI] [PMC free article]
[7] Wang ZX, Cao JX, Liu ZP, Cui YX, Li CY, Li D, Zhang XY, Liu JL, Li JL. Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis. World J Gastroenterol. 2014 Jan 28;20(4):1095-106. doi: 10.3748/wjg.v20.i4.1095. [DOI] [PMC free article]
[8] Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, Liu HC, Alexandrou AT, Jones J, Zhao R, Li JJ. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One. 2014 Apr 3;9(4):e93886. doi: 10.1371/journal.pone.0093886. [DOI] [PubMed]
[9] Shimodaira, S.; Sano, K.; Hirabayashi, K.; Koya, T.; Higuchi, Y.; Mizuno, Y.; Yamaoka, N.; Yuzawa, M.; Kobayashi, T.; Ito, K.; et al. Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms’ Tumor 1 in Patients with Advanced Colorectal Cancer. Vaccines 2015, 3, 1004-1018. doi.org/10.3390/vaccines3041004. [DOI]
[10] Yu, J., Sun, H., Cao, W. et al. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol 11, 3 (2022). doi.org/10.1186/s40164-022-00257-2. [DOI]
[11] Masroor Ali Beg M, Aslam M, Ayaz A, Akhtar MS, Zaman W. Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines. Cells. 2025 Sep 16;14(18):1453. doi: 10.3390/cells14181453. [DOI] [PMC free article]
[12] Zhou X, Mo X, Qiu J, Zhao J, Wang S, Zhou C, Su Y, Lin Z, Ma H. Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis. Cancer Manag Res. 2018 Nov 5;10:5363-5372. doi: 10.2147/CMAR.S173201. [DOI] [PMC free article]
Read:
New Treatments for Stage 4 Colon Cancer in Germany
Comprehensive Guide to Colon Cancer Treatment: New and Standard Treatment Options for Bowel Cancer
Top 10 Leading Oncology Hospitals for Cancer Treatment in Germany
